[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-337306-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-337306-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","dna-methylation-profiles-for-breast-cancer-subtype-classifications-a-translational-study-from-microarray-to-methylation-specific-pcr-msp","DNA methylation profiles for breast cancer subtype classifications - A translational study from microarray to methylation-specific PCR (MSP)","","Breast cancer subtypes are categorized by gene expression profiles using immunohistochemistry into Luminal A, Luminal B, HER2+ and triple-negative breast cancer (TNBC), but immunohistochemistry can misclassify. DNA methylation is an epigenetic modification where promoter-region changes alter gene expression. This study identified DNA methylation biomarkers for subtype classification using microarray and methylation-specific PCR (MSP) after bisulfite conversion. Differentially methylated CpGs were obtained for each subtype, enabling potential subtype diagnosis, including 75% and 76% accuracies for Luminal A and B.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/dna-methylation-profiles-for-breast-cancer-subtype-classifications-a-translational-study-from-microarray-to-methylation-specific-pcr-msp/337306/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/dna-methylation-profiles-for-breast-cancer-subtype-classifications-a-translational-study-from-microarray-to-methylation-specific-pcr-msp/337306.png","ImageObject",300,407,{"name":42,"@type":43},"Ophelia","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why can immunohistochemistry lead to misclassification of breast cancer subtypes?","Question",{"text":63,"@type":64},"Immunohistochemistry relies on semiquantitative interpretation and can show interobserver variability. Reproducibility issues (e.g., Ki-67) and consistent misclassification patterns have been reported.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What methods were used to identify DNA methylation biomarkers in this study?",{"text":68,"@type":64},"DNA samples underwent bisulfite conversion and were analyzed using both microarray profiling and methylation-specific PCR (MSP).",{"name":70,"@type":61,"acceptedAnswer":71},"Which DNA methylation biomarkers were reported for each breast cancer subtype?",{"text":72,"@type":64},"Luminal A showed ADAMTSL2 hypermethylation (cg14397888), Luminal B showed ADAMTSL2 hypomethylation (cg14397888), HER2+ showed PTPRN2 hypermethylation (cg25910261), and TNBC showed LCLAT1 hypomethylation (cg15652532).","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},337306,1790350175,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},7971461741311,"https://ap-avatar.wpscdn.com/avatar/74000253aff267980c6?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779345379180704826","under NC 4.0.  \nOriginal Article  \nDNA methylation profiles for breast cancer subtype classifications: A translational study from microarray to methylation-specific PCR (MSP)  \nSonar S. Panigoro1*, Rafika I. Paramita2,3,4* , Septelia I. Wanandi5,6,7, Fadilah Fadilah3,4, I GNG. Wibisana1 and Noorwati Sutandyo8,9  \n1 Division of Surgical Oncology, Department of Surgery, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia;  \n2Doctoral Program in Biomedical Sciences, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; 3Department of Medical Chemistry, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; 4Bioinformatics Core FacilitiesIMERI, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; 5Master Program in Biomedical Sciences, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; 6Department of Biochemistry and Molecular Biology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; 7Molecular Biology and Proteomics Core Facilities – IMERI, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; 8Department of Hematology and Medical Oncology, Dharmais National Cancer Center Hospital, Jakarta, Indonesia; 9Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia  \n*Corresponding authors: [sonar.soni@ui.ac.id](sonar.soni@ui.ac.id) (SSP); [rafikaindah@ui.ac.id](rafikaindah@ui.ac.id) (RIP)  \nAbstract  \nBreast cancer subtypes can be categorized based on their gene expression profiles using immunohistochemistry into Luminal A, Luminal B, human epidermal growth factor receptor 2-positive (HER2+), and triple-negative breast cancer (TNBC) subtypes. However, immunohistochemistry has certain limitations that can lead tomisclassification. DNA methylation is an epigenetic modification, and changes in the promoter region can alter gene expression and the quantity of functional protein synthesized, disrupting gene function. The aim of this study was to identify DNA methylation biomarkers for subtype classification in breast cancer using microarray and methylation-specific polymerase chain reaction (MSP) methods. DNA samples were extracted, subjected to bisulfite conversion and then used for both the microarray and MSP methods. This study successfully identified differentially methylated CpGs (DMCs) as biomarker for each subtype classification of breast cancer: Luminal A (hypermethylation of ADAMTSL2 gene; cg14397888), Luminal B (hypomethylation of ADAMTSL2 gene; cg14397888), HER2+ (hypermethylation of PTPRN2 gene; cg25910261), and TNBC (hypomethylation of LCLAT1 gene; cg15652532) . The DMC biomarker found for the HER2+ subtype, hypermethylation in the PTPRN2 gene (cg25910261), has the potential to be used by healthcare providers to identify HER2+ patients and provide the HER2-targeted therapy to improve the patient’s survival. In addition, our developed MSP method could produce an effective diagnostic tool for classifying the Luminal A and Luminal B subtypes, with accuracies of 75% and 76%, respectively.  \nKeywords: Breast cancer, DNA methylation, microarray, methylated-specific PCR, subtype classifications  \nIntroduction  \nBreast cancer is the most prevalent cancer among women and according to the GLOBOCAN  \n,  \n2022 data, breast cancer had the highest incidence rate in Indonesia, with 66,271 cases, and the  \nOriginal Article  \nPanigoro et al. Narra J 2025; 5 (1): e1364-[http://doi.org/10.52225/narra.v5i1.1364](http://doi.org/10.52225/narra.v5i1.1364)  \nnumber increased compared to previous years [1] . In the same year, the 5-year breast cancer prevalence was 151.3 per 100,000 people in the country, with a 9.3% mortality rate, surpassing the global mortality rate of 6.9%[1] . Currently, breast cancer subtypes can be categorized based on their gene expression profile using immunohistochemistry (IHC) [2] . The standard IHC tests performed for breast cancer include estrogen receptor (ER), progesterone receptor (PR), human epidermal g","cbCaibthdG1V11hY","https://ap.wps.com/l/cbCaibthdG1V11hY","pdf",837443,14,"English","# Abstract\n# Introduction\n## Immunohistochemistry-based subtype classification and limitations\n## Role of DNA methylation and CpG promoter effects","[{\"question\":\"Why can immunohistochemistry lead to misclassification of breast cancer subtypes?\",\"answer\":\"Immunohistochemistry relies on semiquantitative interpretation and can show interobserver variability. Reproducibility issues (e.g., Ki-67) and consistent misclassification patterns have been reported.\"},{\"question\":\"What methods were used to identify DNA methylation biomarkers in this study?\",\"answer\":\"DNA samples underwent bisulfite conversion and were analyzed using both microarray profiling and methylation-specific PCR (MSP).\"},{\"question\":\"Which DNA methylation biomarkers were reported for each breast cancer subtype?\",\"answer\":\"Luminal A showed ADAMTSL2 hypermethylation (cg14397888), Luminal B showed ADAMTSL2 hypomethylation (cg14397888), HER2+ showed PTPRN2 hypermethylation (cg25910261), and TNBC showed LCLAT1 hypomethylation (cg15652532).\"}]","DNA methylation profiles for breast cancer subtype classifications - A translational study from microarray to methylation-specific PCR (MSP) | PDF",1790018539,35,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/aac957b7f77b89f221f77d1340e7d871.webp",983,1390,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7d9552aa691993ab3d296e2100e3dce2.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2a90555659760ea77108d93f5573781c.webp",981,1387,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0896fb187b3006d4600b871408eb662f.webp",980,1385]